Table 1.
Characteristics of AD patients, FTD patients, and controls
| Subject details | Controls (n = 15) | AD patients (n = 13) | Sporadic FTD (n = 16) | C9orf72 FTD (n = 7) | GRN FTD (n = 9) |
|---|---|---|---|---|---|
| Gender (M/F) | 5:10 | 5:8 | 10:6 | 6:1 | 3:6 |
| Age, years (mean ± SD) | 61.0 ± 9.9 | 72.1 ± 6.8 | 71.8 ± 7.3 | 66.0 ± 8.0 | 63.5 ± 8.5 |
| APOE ε4 positive (%) | 13.3% | 69.2% | 56.2% | 14.2% | 22% |
| CSF Biomarkers | |||||
| Aβ1-42 (pg/mL), median (IQR) | 895 (794–1132) | 446 (331.2–498.5) | 656 (552.3–741.8) | 839 (692–1141) | 841 (687–1314) |
| T-tau (pg/mL), median (IQR) | 91 ± (59-155) | 481 (264–666) | 688 (173–1114) | 291 (239–367) | 328 (268–440) |
| P-tau (pg/mL), median (IQR) | 20.5 (17–28) | 84 (56–105) | 72 (28–107) | 68 (38–84) | 27(17–33) |
Data expressed as mean ± SD or median (IQR) as appropriate.